From Screening to Fracture Prevention

In osteoporosis care, a T-score becomes useful only when it enters a pathway with a defined population, a clinical question and a possible response. This chapter follows that pathway from deciding whom to screen through DXA, interpretation and management. It also asks what screening trials actually tested and why the same measurements can appear in different guideline sequences without producing one universal rule.

Eligibility changes the meaning of screening

Screening is not the same as investigating a known problem. The 2025 recommendation from the US Preventive Services Task Force applies to adults aged 40 years or older who do not have known osteoporosis or a history of fragility fractures. It does not apply to people whose bone loss is secondary to an underlying condition such as cancer, metabolic bone disease or hyperthyroidism, or to chronic use of a medication such as a glucocorticoid that is associated with bone loss.

That boundary is easy to miss when a bone-density test is treated as a general health check. A person with a prior fragility fracture may need evaluation and management for a different reason from someone being screened before any known fracture. Likewise, someone taking a medication associated with bone loss may require attention to the cause and exposure rather than being placed into a pathway designed for people without those conditions. The same DXA technology can be used in both situations, but the purpose of the test and the evidence for what follows are not automatically the same.

The word “screening” also describes a decision about a population, not a guarantee about an individual result. It asks whether testing people in a defined group, followed by appropriate care, produces more benefit than harm. That question depends on who is invited, what test is used, how abnormal results are handled and whether effective management is available afterward. A recommendation for one group cannot be copied into another group simply because the same DXA machine can be used. The starting risk, possible causes of bone loss and evidence for treatment may all be different.

For women aged 65 years or older, the USPSTF recommends screening for osteoporosis to prevent osteoporotic fractures with DXA BMD, with or without fracture-risk assessment. The recommendation is not that the scan itself prevents a fracture. The intended benefit depends on what happens after the result: women found to have osteoporosis should be further evaluated, counseled and, when appropriate, offered evidence-based management.

The pathway is more selective for postmenopausal women younger than 65 years. The USPSTF suggests first looking for one or more risk factors for osteoporosis and fracture, in addition to postmenopausal status. Examples include low body weight, a parental history of hip fracture, cigarette smoking and excess alcohol consumption. For someone with at least one risk factor, a clinical risk assessment tool can help determine whether the person is at increased risk and whether DXA screening is warranted.

This two-step process gives the clinical assessment a gatekeeping role without making it the final measurement. The risk factors help identify who should receive closer assessment. The tool helps estimate risk or identify likely osteoporosis, depending on its design. DXA then supplies a central BMD measurement that can be interpreted with the rest of the information. A risk tool may reduce unnecessary testing in a population, but it does not turn an estimate into a diagnosis.

Each transition preserves a different kind of information. The history supplies context that a scan cannot see. The risk tool organizes selected context into an estimate or a testing prompt. DXA adds a site-specific density measurement. Interpretation connects these pieces to the clinical outcome of concern.